Perigon Wealth Management LLC lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1,306.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 1,772 shares of the medical research company’s stock after acquiring an additional 1,646 shares during the period. Perigon Wealth Management LLC’s holdings in IQVIA were worth $342,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in IQV. Optimal Asset Management Inc. lifted its stake in shares of IQVIA by 6.8% in the 1st quarter. Optimal Asset Management Inc. now owns 4,700 shares of the medical research company’s stock valued at $908,000 after acquiring an additional 300 shares during the last quarter. Twinbeech Capital LP lifted its holdings in IQVIA by 384.5% in the first quarter. Twinbeech Capital LP now owns 14,050 shares of the medical research company’s stock worth $2,714,000 after buying an additional 11,150 shares during the period. Capital Analysts LLC boosted its position in shares of IQVIA by 8.6% during the first quarter. Capital Analysts LLC now owns 596 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares in the last quarter. FORA Capital LLC purchased a new stake in shares of IQVIA in the 1st quarter worth about $681,000. Finally, Gotham Asset Management LLC purchased a new stake in IQVIA in the first quarter worth about $602,000. Institutional investors own 86.31% of the company’s stock.
A number of analysts have commented on IQV shares. Truist Securities lifted their target price on IQVIA from $235.00 to $260.00 and gave the stock a “buy” rating in a report on Monday, April 26th. Barclays lifted their price objective on IQVIA from $260.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, July 13th. Jefferies Financial Group raised their price target on IQVIA from $259.00 to $273.00 and gave the company a “buy” rating in a report on Friday, April 23rd. KeyCorp upped their target price on shares of IQVIA from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, May 14th. Finally, Citigroup raised their price target on IQVIA from $225.00 to $265.00 in a report on Friday, April 23rd. Two equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. IQVIA has a consensus rating of “Buy” and a consensus price target of $248.84.
IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, April 22nd. The medical research company reported $2.18 EPS for the quarter, beating the consensus estimate of $1.85 by $0.33. IQVIA had a net margin of 3.40% and a return on equity of 20.96%. The business had revenue of $3.41 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same quarter in the previous year, the business posted $1.50 EPS. The company’s quarterly revenue was up 23.8% compared to the same quarter last year. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 8.15 EPS for the current fiscal year.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also: What is a back-end load?
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.